Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

n-GAAP earnings are projected

to rise to approximately $7.00 per diluted share by 2011.

-- Myozyme sales are expected to be approximately $275-$285 million this

year, compared to prior guidance of $320-$330 million.

-- Non-GAAP earnings per share for the second quarter are expected to be

in the mid $0.90s, reflecting ongoing investments to drive future

growth. These include investments in the U.S. launch of Renvela(R)

(sevelamer carbonate) and the expanded European introduction of

Clolar(R) (clofarabine), as well as investments in late-stage clinical

trials-particularly the phase 3 study of alemtuzumab for multiple

sclerosis. This estimate also reflects the constraints on U.S. Myozyme

sales.

First-Quarter Product Sales

-- Within the Therapeutics business, worldwide demand for Myozyme remains

robust two years into the product's launch. First-quarter sales rose

78 percent despite the delay in U.S. approval for 2000L production

capacity. Sales increased to $67.3 million from $37.9 million in the

period a year ago, driven by the number of new patients starting

therapy. As announced, the FDA will require Genzyme to submit a BLA to

obtain U.S. commercial approval for Myozyme produced at the 2000L

scale. The agency is expected to act on the application by the end of

this year.

-- First-quarter sales of Cerezyme(R) (imiglucerase for injection) rose 15

percent to $304.3 million, compared with $263.8 million in the previous

first quarter.

-- Sales of Fabrazyme(R) (agalsidase beta) grew 16 percent in the quarter,

rising to $116.5 million from $100.7 million in the first quarter last

year. Fabrazyme has captured more than a two thirds share of the

international market for Fabry disease treatment based on compelling

clinical dat
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014 ... announced the addition of the  "Global Hormone ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,Hormone ... is a means of replacing hormones that ... body. This type of therapy is usually ...
(Date:8/21/2014)... , Aug. 21, 2014 Mathematic studies at ... Harvard University , and funded by the Jeffrey Epstein ... within tumors can be visually identified for elimination. These aggressive ... The study, which shows a topological map of what to ... in cancer research, for while tumor cells can be extracted ...
(Date:8/21/2014)... Ontotext S4 , The Self Service Semantic ... Now the same enterprise hardened text mining, Linked Data ... is available to start-ups and mid-size businesses at a ... do not have resources to evaluate and prototype enterprise ... there is no need for on premise hardware provisioning ...
(Date:8/20/2014)... of patented university inventions licensed to biotechnology firms ... commercialization. To open these roadblocks, the researchers suggest ... the discovery stage could lead to faster commercialization ... derived from discoveries made in university laboratories and ... during clinical trials, which have a high failure ...
Breaking Biology Technology:Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... VEGAS, Aug. 11, 2011 Cord Blood America, Inc ... ), the umbilical cord blood stem cell preservation company ... cells to families nationwide and internationally, today announced revenues of ... 61 percent compared to revenues of $1.79 million in the ...
... involving scientists from The University of Nottingham is pioneering a ... reported in Nature Materials , could pave the way ... generation of computers and data storage devices that are faster, ... group, led by Dr Andrei Khlobystov in the University,s School ...
... Aug. 10, 2011 Genesis Biopharma, Inc. (OTC/BB: ... today announced it has signed a Cooperative Research ... Institute (NCI).  Under the terms of the five-year ... work with Steven A. Rosenberg, M.D., Ph.D., the ...
Cached Biology Technology:Cord Blood America Six Month Revenues Up 61 Percent; Gross Profit Up 100 Percent 2Cord Blood America Six Month Revenues Up 61 Percent; Gross Profit Up 100 Percent 3Nottingham scientists pioneer new method for nanoribbon production 2Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies 2Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies 3
(Date:8/20/2014)... OTTAWA , Aug. 20, 2014 /CNW/ -  ... without warning and can quickly become life threatening for some ... As many as 1.2 million Canadians have food allergies and ... six per cent of children are estimated to have food ... range from mild skin irritations and hives to breathing difficulties ...
(Date:8/20/2014)... VALLEY, Calif., August 19, 2014 -- Bay Area Lyme ... diagnose and simple to cure, applauds new research published ... journal Ticks and Tick-borne Diseases . The ... Northwest California are active throughout the year, making the ... by researchers at California Department of Public Health (CDPH) ...
(Date:8/20/2014)... and seawater signals a relaxing trip to the shore. ... vacation comes with an environmental hitch. When certain sunblock ... can become toxic to some of the ocean,s tiniest ... marine animals. Their study appears in the ACS journal ... and David Snchez-Quiles point out that other than staying ...
Breaking Biology News(10 mins):Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3
... 2008A landmark genetic study has identified multiple genes linked ... autoimmune disease that affects an estimated 1.4 million Americans. ... lungs, brain and blood and occurs in about 31 ... more likely than men to develop the condition, which ...
... available in French . , A study ... differences between individuals at the DNA level can lead ... These, in turn, are responsible for the vast array ... part of the Genome Regulators in Disease (GRID) Project ...
... from the January issue of Mayo Clinic Proceedings include ... workplace drug screening and the safety and effectiveness of ... Examine the Effect of Antioxidant Supplements on Cancer ... cancer and deaths related to cancer? Thats a question ...
Cached Biology News:Steps toward Stopping Autoimmune Disease 2Tiny genetic differences have huge consequences: McGill researchers 2Mayo Clinic Proceedings January tip sheet 2Mayo Clinic Proceedings January tip sheet 3
Anti-Mouse C-10, Biotin (Polyclonal) (rabbit IgG)...
... ADAMTS16 ( Abpromise for all ... Synthetic peptide based on the ... the amino acid sequence is proprietary) ... 170690 SWISS Protein ...
Purified Mouse anti-Hu Actopaxin (pS8) Storage Temperature: Refrigerate(2 to 8C)...
Hamartin/TSC1 (1B2) Mouse mAb Ship: Hot Store: -20 C...
Biology Products: